CVS Health Corporation $CVS Position Trimmed by Cwm LLC

Cwm LLC decreased its holdings in shares of CVS Health Corporation (NYSE:CVS) by 23.5% in the 2nd quarter, Holdings Channel reports. The firm owned 79,369 shares of the pharmacy operator’s stock after selling 24,435 shares during the quarter. Cwm LLC’s holdings in CVS Health were worth $5,475,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in CVS. Goldman Sachs Group Inc. increased its stake in CVS Health by 87.5% during the first quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator’s stock valued at $672,598,000 after purchasing an additional 4,632,530 shares during the last quarter. Dodge & Cox grew its position in shares of CVS Health by 4.8% during the first quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after acquiring an additional 3,353,223 shares during the last quarter. Nuveen LLC bought a new position in shares of CVS Health during the first quarter worth about $204,421,000. Invesco Ltd. grew its position in shares of CVS Health by 13.2% during the first quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock worth $1,383,039,000 after acquiring an additional 2,375,764 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its position in shares of CVS Health by 815.2% during the second quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock worth $183,701,000 after acquiring an additional 2,372,121 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Price Performance

Shares of NYSE CVS opened at $80.75 on Thursday. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $81.93. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $102.42 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 0.88 and a beta of 0.60. The firm has a 50-day moving average of $73.30 and a two-hundred day moving average of $67.92.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.46 by $0.35. CVS Health had a net margin of 1.17% and a return on equity of 10.51%. The company had revenue of $98.92 billion during the quarter, compared to the consensus estimate of $94.87 billion. During the same period in the prior year, the company earned $1.83 EPS. CVS Health’s revenue was up 8.4% on a year-over-year basis. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Thursday, October 23rd. CVS Health’s dividend payout ratio is presently 74.30%.

Insiders Place Their Bets

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the company’s stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the sale, the director directly owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. This represents a 25.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 1.22% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on CVS shares. UBS Group upgraded shares of CVS Health from a “neutral” rating to a “buy” rating and upped their price target for the stock from $67.00 to $79.00 in a research report on Monday, August 18th. Barclays upped their price target on shares of CVS Health from $80.00 to $87.00 and gave the stock an “overweight” rating in a research report on Thursday, September 4th. Bernstein Bank decreased their target price on shares of CVS Health from $78.00 to $72.00 and set a “market perform” rating for the company in a research report on Wednesday, July 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of CVS Health in a research report on Tuesday. Finally, Cowen reiterated a “buy” rating on shares of CVS Health in a research report on Monday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $81.05.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.